A New Approach to Stem Cell Maturation
Article Feb 07, 2017 | By Anna MacDonald, Editor for Technology Networks
Credit: Chulan Kwon
An interview with Dr. Chulan Kwon, Associate Professor of Medicine, Johns Hopkins Medicine.
Until now, the generation of viable heart muscle cells from pluripotent stem cells has had limited success, with several protocols reporting the resulting heart cells remaining immature in a dish even after a year of culture. This immaturity has emerged as a major obstacle for modelling and treating late-onset heart disease such as cardiomyopathy that manifests predominantly in adults, notes Chulan.
Research in the Kwon lab centres around understanding heart generation and regeneration, with particular focus on the regenerative biology of cardiac progenitors and cardiomyocytes. Recently, the lab has developed a new method of creating mature cardiac muscle cells derived from pluripotent stem cells, using rodent hearts as a bioreactor.
Chulan states that the benefits of this approach are that “the neonatal environment provides potent cues absent in culture for cell maturation. Moreover, the process can be done in an accelerated fashion.”
It is hoped that this process could lead to advances in the understanding of heart disease and provision of precision medicine. “The method enables us to generate mature cardiac muscle cells from patients, which can be utilized for elucidating patient-specific pathogenesis of adult-onset heart muscle disease as well as for personalized drug testing” says Chulan.
The method is not just limited to heart cells, and the Kwon lab has plans to expand the method to generate other types of mature cells prone to disease. This could be fundamental in the development of diagnostics and identification of treatments for a range of diseases.
To follow progress of this work and other research from Chulan’s lab, please visit http://www.ck-laboratory.org/home.html
A Chinese scientist, He Jiankui, has claimed that he helped make the world-first gene-edited babies: two twin baby girls. Reportedly, he used CRISPR-Cas9 to edit embryos for seven couples during IVF fertility treatment, and engineered the embryos to possess resistance to HIV infection. He Jiankui, from the Southern University of Science and Technology, is now facing investigation over whether the experiment was illegal.READ MORE
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
3rd Annual DIGI-TECH PHARMA 2019 Conference & Expo
May 21 - May 22, 2019